This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okamoto, A. Articles by Yokota, J. Search for Related Content PubMed Articles by Okamoto, A. Articles by Yokota, J.

Allelic Loss on Chromosome 17p and p53 Mutations in Human Endometrial Carcinoma of the Uterus¹

National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104 [A. O., Y. S., Y. Y., S. T., M. T., J. Y.], and Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 25-8, Nishi-Shinbashi, Minato-ku, Tokyo 105 [Y. T.], Japan

To understand the involvement of allelic losses and inactivation of tumor suppressor genes for the development of endometrial carcinoma of the uterus (EC), 24 cases of EC were examined for loss of heterozygosity (LOH) using a total of 57 polymorphic DNA markers covering all 23 pairs of chromosomes. LOH was observed at 27 loci on 10 different chromosomes, i.e., chromosomes 1, 3, 6, 11, 13, 15, 17, 18, 20, and 21, but was not detected at loci on chromosomes 4, 5, 7, 9, 10, 12, 14, 16, and X. It was observed only in seven of 24 cases, and the other 19 cases did not show LOH at any loci examined, including five cases of tumors with a high proportion of adenomatous hyperplasia. Among seven tumors with LOH at one or more loci, five tumors showed LOH at loci on the short arm of chromosome 17. Furthermore, mutations of the p53 gene, which is located on the short arm of chromosome 17, were detected in three of these 24 tumors by a polymerase chain reaction-single strand conformation polymorphism analysis and subsequent DNA sequencing. In two of these three tumors, p53 mutations were accompanied by the loss of wild-type p53 alleles. These results suggest that inactivation of the p53 gene is involved in the development of EC as in the case of several other types of human cancers.

¹ This work was supported in part by a Grant-in-Aid for a Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare of Japan, and Grants-in-Aid from the Ministry of Health and Welfare and the Ministry of Education, Science and Culture of Japan. Y. S. and Y. Y. are awardees of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research.

² To whom requests for reprints should be addressed, at Section of Studies on Metastasis, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104, Japan.

Received 5/20/91. Accepted 8/ 2/91.

This article has been cited by other articles:

				D. Brinkmann, A. Ryan, A. Ayhan, W. G. McCluggage, R. Feakins, M. F. Santibanez-Koref, C. A. Mein, S. A. Gayther, and I. J. Jacobs A Molecular Genetic and Statistical Approach for the Diagnosis of Dual-Site Cancers J Natl Cancer Inst, October 6, 2004; 96(19): 1441 - 1446. [Abstract] [Full Text] [PDF]

				J. I. Risinger, G. L. Maxwell, G. V. R. Chandramouli, A. Jazaeri, O. Aprelikova, T. Patterson, A. Berchuck, and J. C. Barrett Microarray Analysis Reveals Distinct Gene Expression Profiles among Different Histologic Types of Endometrial Cancer Cancer Res., January 1, 2003; 63(1): 6 - 11. [Abstract] [Full Text] [PDF]

				T. Minaguchi, H. Yoshikawa, K. Oda, T. Ishino, T. Yasugi, T. Onda, S. Nakagawa, K. Matsumoto, K. Kawana, and Y. Taketani PTEN Mutation Located Only Outside Exons 5, 6, and 7 Is an Independent Predictor of Favorable Survival in Endometrial Carcinomas Clin. Cancer Res., September 1, 2001; 7(9): 2636 - 2642. [Abstract] [Full Text] [PDF]

				H. A. ARANGO, S. ICELY, W. S. ROBERTS, D. CAVANAGH, and J. L. BECKER Aspirin Effects on Endometrial Cancer Cell Growth Obstet. Gynecol., March 1, 2001; 97(3): 423 - 427. [Abstract] [Full Text] [PDF]

				S. S. E. Fernando, X. Wu, and L. S. Perera p53 Overexpression and Steroid Hormone Receptor Status in Endometrial Carcinoma International Journal of Surgical Pathology, July 1, 2000; 8(3): 213 - 222. [Abstract] [PDF]

				T. Segawa, T. Sasagawa, K. Saijoh, and M. Inoue Clinicopathological Significance of Fragile Histidine Triad Transcription Protein Expression in Endometrial Carcinomas Clin. Cancer Res., June 1, 2000; 6(6): 2341 - 2348. [Abstract] [Full Text]

				X. Zhou, X. W. Wang, L. Xu, K. Hagiwara, M. Nagashima, R. Wolkowicz, I. Zurer, V. Rotter, and C. C. Harris COOH-Terminal Domain of p53 Modulates p53-mediated Transcriptional Transactivation, Cell Growth, and Apoptosis Cancer Res., February 1, 1999; 59(4): 843 - 848. [Abstract] [Full Text] [PDF]